Ultrasound-Guided Percutaneous Neuromodulation on the Superior Gluteal Nerve in Patients With Greater Trochanteric Pain Syndrome: A Pilot Study
NCT Number: NCT06529783
Status: NOT_YET_RECRUITING
Study Type: INTERVENTIONAL
Phases: NA
Conditions: Greater Trochanteric Pain Syndrome
Interventions: OTHER: Shockwave Therapy|OTHER: Therapeutic Exercises|OTHER: Ultrasound-Guided Percutaneous Neuromodulation:
Sponsor: Universidad de Zaragoza
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 50
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER
Start Date: 2024-09-30
Completion Date: 2025-04-30
Locations: University of Zaragoza, Zaragoza, 50009, Spain

Summary:
Greater Trochanteric Pain Syndrome (GTPS) predominantly affects women, with an annual incidence of 1.8 to 5.6 per 1000 individuals and a prevalence ratio of 4:1 compared to men. It is characterized by lateral pain in the greater trochanter region, particularly during palpation, prolonged sitting, and physical activity. Conservative treatments, such as radial shockwave therapy and therapeutic exercises, are effective but slow, and some patients eventually require surgery.

Ultrasound-guided percutaneous neuromodulation, targeting the superior gluteal nerve, has emerged as a promising alternative to improve GTPS outcomes. This technique aims to normalize motor response and reduce pain more rapidly than conventional therapies. Integrating neuromodulation could accelerate recovery, enhancing both pain relief and tendon functionality. This study aims to explore the effectiveness of this technique as an adjunct to conventional treatments, aiming for faster symptom improvement and better long-term adherence.

Primary Outcome Measures: Functional capacity, Functionality will be assessed using the Visa-G questionnaire, which consists of 8 questions divided into three main aspects: pain, function, and activity. The first 7 questions score up to 10 points each, while question 8 has a maximum score of 30. An asymptomatic person would score a total of 100 points; thus, a lower score indicates greater disability severity., This variable is measured five times, corresponding with the five participant visits (day 1, week 4, week 8, week 16, and year 1).
Secondary Outcome Measures: Pain on the Day Prior to the Visit, Pain is measured using the Visual Analog Scale (VAS)., This variable is collected on five occasions, coinciding with the five participant visits (day 1, week 4, week 8, week 16, and year 1)|Pain on Palpation of the Greater Trochanter, Pain on palpation, performed by the physiotherapist, is also measured using the VAS, day 1, week 4, week 8, week 16, and year 1|Hip Abductor Muscle Strength, Strength is measured using an Active Force 2 dynamometer, day 1, week 4, week 8, week 16, and year 1|Adverse Effects, Adverse effects for this study include pain during the treatment session, pain after the session, inflammation and/or redness in the treated area, bruising in the treated region, dizziness, muscle fatigue, numbness, and drowsiness. These are assessed through the participant's oral reports., day 1, week 4, week 8, week 16, and year 1|Adherence to the Therapeutic Exercise Protocol, Adherence is assessed by asking the patient in each session if they are following the protocol correctly, with an emphasis on honesty to ensure accurate recording of adherence., day 1, week 4, week 8, week 16, and year 1